200 related articles for article (PubMed ID: 20872286)
1. O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.
Premaratne P; Welén K; Damber JE; Hansson GC; Bäckström M
Tumour Biol; 2011 Feb; 32(1):203-13. PubMed ID: 20872286
[TBL] [Abstract][Full Text] [Related]
2. Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice.
Mungul A; Cooper L; Brockhausen I; Ryder K; Mandel U; Clausen H; Rughetti A; Miles DW; Taylor-Papadimitriou J; Burchell JM
Int J Oncol; 2004 Oct; 25(4):937-43. PubMed ID: 15375543
[TBL] [Abstract][Full Text] [Related]
3. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
[TBL] [Abstract][Full Text] [Related]
4. Recombinant MUC1 probe authentically reflects cell-specific O-glycosylation profiles of endogenous breast cancer mucin. High density and prevalent core 2-based glycosylation.
Müller S; Hanisch FG
J Biol Chem; 2002 Jul; 277(29):26103-12. PubMed ID: 12000758
[TBL] [Abstract][Full Text] [Related]
5. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer.
Sewell R; Bäckström M; Dalziel M; Gschmeissner S; Karlsson H; Noll T; Gätgens J; Clausen H; Hansson GC; Burchell J; Taylor-Papadimitriou J
J Biol Chem; 2006 Feb; 281(6):3586-94. PubMed ID: 16319059
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers.
Chen Z; Gulzar ZG; St Hill CA; Walcheck B; Brooks JD
Prostate; 2014 Jul; 74(10):1059-67. PubMed ID: 24854630
[TBL] [Abstract][Full Text] [Related]
7. MUC1 expression, splice variant and short form transcription (MUC1/Z, MUC1/Y) in prostate cell lines and tissue.
Schut IC; Waterfall PM; Ross M; O'Sullivan C; Miller WR; Habib FK; Bayne CW
BJU Int; 2003 Feb; 91(3):278-83. PubMed ID: 12581019
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.
Brockhausen I; Yang JM; Burchell J; Whitehouse C; Taylor-Papadimitriou J
Eur J Biochem; 1995 Oct; 233(2):607-17. PubMed ID: 7588808
[TBL] [Abstract][Full Text] [Related]
9. Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines.
Poland PA; Kinlough CL; Rokaw MD; Magarian-Blander J; Finn OJ; Hughey RP
Glycoconj J; 1997 Jan; 14(1):89-96. PubMed ID: 9076518
[TBL] [Abstract][Full Text] [Related]
10. Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells.
Suwa T; Hinoda Y; Makiguchi Y; Takahashi T; Itoh F; Adachi M; Hareyama M; Imai K
Int J Cancer; 1998 May; 76(3):377-82. PubMed ID: 9579575
[TBL] [Abstract][Full Text] [Related]
11. A MUC1 tandem repeat reporter protein produced in CHO-K1 cells has sialylated core 1 O-glycans and becomes more densely glycosylated if coexpressed with polypeptide-GalNAc-T4 transferase.
Olson FJ; Bäckström M; Karlsson H; Burchell J; Hansson GC
Glycobiology; 2005 Feb; 15(2):177-91. PubMed ID: 15456735
[TBL] [Abstract][Full Text] [Related]
12. Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells.
Bäckström M; Link T; Olson FJ; Karlsson H; Graham R; Picco G; Burchell J; Taylor-Papadimitriou J; Noll T; Hansson GC
Biochem J; 2003 Dec; 376(Pt 3):677-86. PubMed ID: 12950230
[TBL] [Abstract][Full Text] [Related]
13. MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 β1,6-N-acetylglucosaminyltransferase and β-galactoside α2,3-sialyltransferase.
Solatycka A; Owczarek T; Piller F; Piller V; Pula B; Wojciech L; Podhorska-Okolow M; Dziegiel P; Ugorski M
Glycobiology; 2012 Aug; 22(8):1042-54. PubMed ID: 22534569
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1.
Ryuko K; Schol DJ; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Karuntu-Wanamarta YA; Verstraeten RA; Miyazaki K; Kenemans P; Hilgers J
Tumour Biol; 2000; 21(4):197-210. PubMed ID: 10867613
[TBL] [Abstract][Full Text] [Related]
15. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer.
Curry JM; Thompson KJ; Rao SG; Besmer DM; Murphy AM; Grdzelishvili VZ; Ahrens WA; McKillop IH; Sindram D; Iannitti DA; Martinie JB; Mukherjee P
J Surg Oncol; 2013 Jun; 107(7):713-22. PubMed ID: 23335066
[TBL] [Abstract][Full Text] [Related]
16. MUC1 expression in human prostate cancer cell lines and primary tumors.
O'Connor JC; Julian J; Lim SD; Carson DD
Prostate Cancer Prostatic Dis; 2005; 8(1):36-44. PubMed ID: 15477874
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule.
Satoh S; Hinoda Y; Hayashi T; Burdick MD; Imai K; Hollingsworth MA
Int J Cancer; 2000 Nov; 88(4):507-18. PubMed ID: 11058865
[TBL] [Abstract][Full Text] [Related]
18. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human tumor antigen MUC1 expressed in insect cells: structure and immunogenicity.
Soares M; Hanisch FG; Finn OJ; Ciborowski P
Protein Expr Purif; 2001 Jun; 22(1):92-100. PubMed ID: 11388805
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of KL-6/MUC1 glycosylation limits aggressive progression of pancreatic cancer.
Xu HL; Zhao X; Zhang KM; Tang W; Kokudo N
World J Gastroenterol; 2014 Sep; 20(34):12171-81. PubMed ID: 25232251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
